Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.
Letrozole was not superior to anastrazole with respect to efficacy or safety in postmenopausal women with HR-positive, node-positive early breast cancer.
Greater negative beliefs regarding the challenges of their aromatase inhibitor treatment more likely to lead to nonadherence.
Oncology nurses can play a pivotal role in diagnosis and management of the rare neuroendocrine tumors pheochromocytomas and paragangliomas.
The risk of the most serious cardiovascular events, including cardiac ischemia and stroke, was not higher for breast cancer survivors who received an aromatase inhibitor (AI) compared with tamoxifen users.
The impact on quality of life for patients with breast cancer receiving adjuvant endocrine therapy (ET) should be given more attention, and clinicians should make better efforts to address patient-reported outcomes.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|